Compass pathways stock forecast.

These psychedelic sector stocks are generating a buzz among investors. ... Compass Pathways PLC -26.3%: Incannex Healthcare Ltd. -69.6% ... Commercial Real Estate Outlook for 2024.

Compass pathways stock forecast. Things To Know About Compass pathways stock forecast.

A. While ratings are subjective and will change, the latest Compass Pathways ( CMPS) rating was a reiterated with a price target of $0.00 to $21.00. The current price Compass Pathways ( CMPS) is ...May 13, 2022 · COMPASS Pathways has a market cap of $299.3 million, and a 52-week range of $6.74 to $49.52. The stock has a price/book ratio of 1.32, and a price-to-free-cash-flow ratio of -6.9. Psychedelics biotech giant COMPASS Pathways (NASDAQ:CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select group ...17 ต.ค. 2565 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics.Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has entered into a securities purchase agreement with a select group of healthcare specialist investors for the private placement of (i) 16,076,750 …

markets.businessinsider.com - August 7 at 4:42 PM. HC Wainwright Reiterates "Buy" Rating for COMPASS Pathways (NASDAQ:CMPS) marketbeat.com - August 4 at 2:37 PM. Compass Pathways Plc (CMPS) Q2 2023 Earnings Call Transcript. finance.yahoo.com - August 4 at 4:00 AM. COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady …

However, the expert forecasts the stock moving up to $25, implying 252% upside potential. If so, FAT would easily be one of the sin stocks to buy. Compass Pathways (CMPS)

Past 5 Years (per annum) N/A. N/A. N/A. N/A. See COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.WebCMPS: Get the latest COMPASS Pathways stock price and detailed information including CMPS news, historical charts and realtime prices. Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Ce...May 13, 2022 · COMPASS Pathways has a market cap of $299.3 million, and a 52-week range of $6.74 to $49.52. The stock has a price/book ratio of 1.32, and a price-to-free-cash-flow ratio of -6.9. View Our Latest Research Report on COMPASS Pathways. COMPASS Pathways Price Performance. COMPASS Pathways stock opened at $6.01 on Friday. The firm has a market cap of $372.02 million, a P/E ratio of -2.32 and a beta of 2.56. The stock’s 50 day moving average is $6.75 and its 200 day moving average is $7.90.

According to 5 stock analysts, the average 12-month stock price forecast for CMPS stock stock is $49.6, which predicts an increase of 722.55%. The lowest target is $19 and the highest is $120. On average, analysts rate CMPS stock stock as a strong buy.

Cash position at 30 June 2022 of $207.2 million. Conference call today at 8:00am ET (1:00pm UK) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to ...

It's a gradual path, however, and the stock hasn't moved much overall since the company last provided a financial update on Aug. 11. But in the month of September, Compass shares slid 11.9% ...View the latest COMPASS Pathways PLC ADR (CMPS) stock price, news, historical charts, analyst ratings and financial information from WSJ.Apr 26, 2021 · Shares of psychedelics-inspired medicine developer COMPASS Pathways (NASDAQ: CMPS) jumped more than 5% on Monday, continuing what has been a multi-day uptrend for CMPS stock.; CMPS stock is now up ... Get the latest COMPASS Pathways plc (CMPS) stock news and headlines to help you in your trading and investing decisions. ... Performance Outlook. Short Term. 2W - 6W. Mid Term. 6W - 9M. Long Term ...Web49.33R USD +43.50 +746.20%. The 6 analysts offering 1 year price forecasts for COMPASS Pathways Plc - American Depository Shares have a max estimate of 120.00 …

In August 2023 COMPASS Pathways announced a major private placement that initially eased concerns regarding group’s cash runway. Find out why CMPS stock is a Sell.Description. Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways …These psychedelic stocks are speculative but could potentially offer massive upside. MindMed ( MNMD ): Positioned to rapidly expand its GAD therapy this year. COMPASS Pathways ( CMPS ): COMP360 ...The financials. The average price target from the nine analysts following COMPASS pathways is $68 against a current price of $14.9, implying a 356% upside and a target market cap of $3 billion. I ...CMPS Earnings Date and Information. COMPASS Pathways last posted its quarterly earnings data on November 2nd, 2023. The reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.17. COMPASS Pathways has generated ($2.59) earnings per share over the last year ( ($2.59) diluted …WebThe average price target is $46.83, with a high forecast of $120.00 and a low forecast of $19.00. ... The current consensus among 5 investment analysts is to buy stock in COMPASS Pathways. This Buy consensus rating has held steady for over two years. Past Monthly Recommendations.10 stocks we like better than COMPASS Pathways When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, ...

View Our Latest Research Report on COMPASS Pathways. COMPASS Pathways Price Performance. COMPASS Pathways stock opened at $6.01 on Friday. The firm has a market cap of $372.02 million, a P/E ratio of -2.32 and a beta of 2.56. The stock’s 50 day moving average is $6.75 and its 200 day moving average is $7.90.

Jul 2, 2023 · COMPASS Pathways is a mental healthcare company that specializes in psilocybin therapy. Read more to see my thoughts on CMPS stock and why it is a Hold. ... CMPS Stock Forecast. Company's cash position stands at $248.0 million with a net loss of $33.4 million for Q3 2023. Get the latest COMPASS Pathways plc (CMPS) stock news and headlines to help you in your trading and ... Financial highlights. Net loss for the three months ended 31 March 2023 was $24.2 million, or $0.57 loss per share (including non-cash share-based compensation expense of $4.1 million), compared with $21.2 million or $0.50 loss per share, during the same period in 2022 (including non-cash-share-based compensation expense of $3.1 million).WebThe upgrade of COMPASS Pathways PLC Sponsored ADR to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move ...See COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Upgrade Your Account ... COMPASS Pathways plc NASDAQ: CMPS is a United Kingdom-based mental healthcare company developing psilocybin therapy through late-stage ...Nonetheless, Atai remains one of the leaders in the psychedelics segment of the biotech industry, and it holds a 22.4% stake in Compass Pathways, which is one of the other leaders. So if Compass ...WebFor COMPASS Pathways plc stock forecast for 2023, 2 predictions are offered for each month of 2023 with average COMPASS Pathways plc stock forecast of $5.33, a high forecast of $5.36, and a low forecast of $5.3. The average COMPASS Pathways plc stock forecast 2023 represents a 0.88% increase from the last price of $5.28499984741211.

Psychedelics biotech giant COMPASS Pathways (NASDAQ:CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select group ...

Based on the most recent data, CMPS has returned 5% so far this year. Meanwhile, stocks in the Medical group have lost about 16.7% on average. This means that COMPASS Pathways PLC Sponsored ADR is ...

But buying the stock now could leave the door open for potentially massive upside in a few years if it can get COMP360 on the market. 2. Atai Life Sciences. Much like Compass Pathways, Atai Life ...COMPASS Pathways Stock Price, News & Analysis (NASDAQ:CMPS) $5.98 +0.05 (+0.84%) (As of 04:00 PM ET) Compare Today's Range $5.91 $6.56 50-Day Range $5.27 $7.96 52-Week Range $5.01 $11.48 Volume 900,582 shs Average Volume 342,967 shs Market Capitalization $370.16 million P/E Ratio N/A Dividend Yield N/A Price Target $46.83 ... targets for tomorrow -CMPS Compass Pathways Plc ADR stock price movement predictions for tomorrow,weekly,monthly -NASDAQ Stock Exchange munafasutra.com.Overall, the consensus among analysts is that Compass Pathways has a promising future ahead. CMPS Stock Analysis: Fluctuating Prices and Negative Earnings Growth, but Positive Forecast for the Future. On May 11, 2023, CMPS stock opened at the same price as the previous close, which was 8.59. Throughout the day, the stock’s price fluctuated ...Compass Pathways : ... However, the expert forecasts the stock moving up to $25, implying 252% upside potential. If so, FAT would easily be one of the sin stocks to buy.Past 5 Years (per annum) N/A. N/A. N/A. N/A. See COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.WebThe current Compass Pathways PLC [ CMPS] share price is $6.45. The Score for CMPS is 52, which is 4% above its historic median score of 50, and infers lower risk than normal. CMPS is currently trading in the 50-60% percentile range relative to its …WebCompass Pathways has also returned positive data from a Phase 2 trial of its psilocybin formulation, using a similar "monitored sessions" approach, even providing music, soft furnishings and a ...Nov 27, 2023 · The Compass Pathways PLC stock price fell by -6.05% on the last day (Monday, 27th Nov 2023) from $6.45 to $6.06. During the last trading day the stock fluctuated 13.20% from a day low at $5.80 to a day high of $6.56. The price has risen in 6 of the last 10 days and is up by 14.99% over the past 2 weeks. Volume has increased on the last day by ...

CMPS - COMPASS PATHWAYS PLC. AMERICAN DEPOSITORY SHARES. HOME · Internacional · Stocks ... ASSINATURAS PLANO BULL MÓDULO FORECAST. STATUS INVEST Política de ...About the COMPASS Pathways Plc stock forecast. As of 2023 November 27, Monday current price of CMPS stock is 6.450$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).7 de jul. de 2023 ... COMPASS Pathways PLC (CMPS) stock is trading at $10.70 as of 11:57 AM on Friday, Jul 7, a gain of $1.36, or 14.56% from the previous closing ...In the same quarter last year, COMPASS Pathways's earnings per share (EPS) was -$0.44. COMPASS Pathways is expected to release next earnings on 02/26/2024, with ...Instagram:https://instagram. porter stansburyho2 homeowners policybest fx platformbest mt5 forex broker Nov 9, 2021 · What happened. Compass Pathways ( CMPS 6.61%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ... jfk silver half dollar valuestock ab Dec 1, 2023 · 8 Wall Street research analysts have issued 1-year target prices for Compass' shares. Their COMP share price targets range from $2.25 to $5.00. On average, they expect the company's stock price to reach $3.39 in the next twelve months. This suggests a possible upside of 47.2% from the stock's current price. best value stocks today Learn More. Market Cap. (-2.86%) -$0.17. Current Price. The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic ...WebCompass Pathways has also returned positive data from a Phase 2 trial of its psilocybin formulation, using a similar "monitored sessions" approach, even providing music, soft furnishings and a ...Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression, and launches new research center. Read more. Compass is a biotechnology company dedicated to accelerating patient access and experience to evidence-based innovation in mental health care.